373 results about "Radioactive drug" patented technology

A method and apparatus which frees the operator from dispensing operations with a reduction in exposure. A necessary amount of radioactive drug solution is dispensed by measuring radioactivity concentration of the radioactive drug solution passing through a tube constituting the channel of the radioactive drug solution, and controlling the amount of dispensation.

An algorithm and associated program for performing method steps in the maintaining of records and generating of reports used in the processing of radioactive pharmaceuticals. The algorithm is used as the basis of a program which can accomplish this method automatically. The method involves the determination of dose, the acquisition of the materials, scheduling for the issuance of doses and for future doses, the actual monitoring and control of material and equipment disposal. The algorithm and method are also adapted for the generation of reports on a periodic basis. In short, the method performed by the algorithm allows for an automation through a computer system and this, in turn, allows for the automatic processing of the steps performed and the controls involved in the dispensing of radioactive pharmaceuticals and automatically allows for the generation of governmental and other reports therefor.

Systems, devices, and methods for more accurately determining a radiopharmaceutical dose administered to a patient by relying on a time factor. Particularly, broadly contemplated herein is the administration of a dose on the basis of an elapsed time from when a dose was last accurately measured in the past to when it is injected into the patient. As such, when a dose is first measured, that timepoint is preferably recorded whereupon the time of injection or administration into a patient is also recorded. Based on the original measured dose, the radionuclide (and thus its known decay rate) and the time elapsed, the dose is calculated and not directly measured on injection. The clocks on the filling station and the transport cart are synchronized to each other or to a known and accepted time standard. In this manner, there is temporal continuity and no inaccuracies of time or loss of time occurs between measurement and injection.

Method for preparing, packaging and handling an individual dose of a radiopharmaceutical compound, comprising the following steps: filling a cartridge (1) with said dose of radiopharmaceutical compound via a first end, the second end being closed by means of a component serving as a piston (3); closing said cartridge (1) at said first end by means of a closure device (2); placing said cartridge (1) in a radiation shielding device (10), comprising an inner part (4) and an outer part (5), said inner part serving as radiation shielding for an operator and said outer part serving as a transportation shielding container; closing said container by means of an appropriate shielding lid (6); transporting said container up to the place at which an injection of said radiopharmaceutical compound will take place; removing the shielding lid (6) of the container; fixing a plunger (7) to the cartridge piston (3); extracting the cartridge and the inner part (4) of the radiation shielding device (10) from the outer part (5) serving as a container, and placing injection means (30) on the cartridge end which has the setting closure device (2).

Presented herein are systems and methods that provide for automated analysis of three-dimensional (3D) medical images of a subject in order to automatically identify specific 3D volumes within the 3D images that correspond to specific organs and/or tissue. In certain embodiments, the accurate identification of one or more such volumes can be used to determine quantitative metrics that measure uptake of radiopharmaceuticals in particular organs and/or tissue regions. These uptake metrics can be used to assess disease state in a subject, determine a prognosis for a subject, and/or determine efficacy of a treatment modality.

The invention discloses a pyridazinone compound marked by fluorine-18 with a molecular formula of FFPnOP and a preparation method and applications; in the formula, n is equal to 1, 2 or 3. By technical synthesis to ligand OTs-PnOP, the pyridazinone compound FFPnOP marked by radioactive fluorine-18 and stable reference compound FFPnOP are obtained by synthesis, wherein the stable reference compound is used for confirming the structure of the compound with radioactive marks; the compound has high radiochemical purity, good biological properties, high initial uptake value, simple preparation and low use cost, and is applied in the technical fields of radioactive drug chemistry and clinical nuclear medicine as a novel myocardial perfusion imaging agent marked by fluorine-18.

Presented herein are systems and methods that provide for automated analysis of three-dimensional (3D) medical images of a subject in order to automatically identify specific 3D volumes within the 3D images that correspond to specific anatomical regions (e.g., organs and/or tissue). Notably, the image analysis approaches described herein are not limited to a single particular organ or portion of the body. Instead, they are robust and widely applicable, providing for consistent, efficient, and accurate detection of anatomical regions, including soft tissue organs, in the entire body. In certain embodiments, the accurate identification of one or more such volumes is used to automatically determine quantitative metrics that represent uptake of radiopharmaceuticals in particular organs and/or tissue regions. These uptake metrics can be used to assess disease state in a subject, determine a prognosis for a subject, and/or determine efficacy of a treatment modality.

The present invention relates to stabilised <99m>Tc radiopharmaceutical compositions, which include both a radioprotectant and one or more antimicrobial preservative(s), and hence have an extended lifetime of use. The radioprotectant is ascorbic acid, para-aminobenzoic acid, gentisic acid or a salt thereof with a biocompatible cation, and the antimicrobial preservative is one or more compound from the paraben series of preservatives. The invention is particularly useful for cationic, lipophilic <99m>Tc heart imaging agents such as Myoview(TM).

This invention relates to a method of using radiolabelled and/or radiopharmaceutical small molecule inhibitors of beta-amyloid peptide production for the diagnosis of neurological and other disorders involving APP processing and beta-amyloid production. Furthermore, radiolabelled small molecule inhibitors identified by the methods of the present invention would be useful in the diagnosis of neurological disorders, such as Alzheimer's disease, which involve elevated levels of Aβ peptides.

The invention discloses a preparation method and application of a pyridazinone myocardial perfusion PET radiopharmaceutical. According to the invention, a large-dose initial 18F activity label is adopted, the precursor usage amount of a reaction, the reaction temperature and the purification HPLC condition are optimized, the reaction yield is improved, the preparation amount of [18F]Fmpp2 can reach 200 mCi, the chemical impurity amount is reduced, the radiochemical purity is high, and the key quality index is kept stable within 6 hours. A method for preparing a [18F]Fmpp2 solution for injection is improved, and the radiochemical purity and stability of the [18F]Fmpp2 are improved. The [18F]Fmpp2 prepared by the invention is subjected to miniature pig myocardial model PET imaging display; after the [18F]Fmpp2 is intravenously injected, the myocardial radioactive uptake is high, and the influence of peripheral organs on myocardial development is small; and normal myocardium, ischemic myocardium caused by chronic coronary artery stenosis and infarcted myocardium caused by acute coronary artery stenosis can be distinguished.

The invention provides a precursor compound of a PET agent and a preparation method and application of the precursor compound, which belong to the field of radiopharmaceutical labeling. The PET agentand the compound are simple to prepare, short in preparation time and high in radiochemical yield, have the advantages of good in-vivo and in-vitro stability, high specificity, high intake and the like, and can be used for accurately and stably detecting and positioning tumor or inflammatory parts.

A syringe shield used for containing radioactive drugs in order to reduce healthcare provider's exposure to radiation or to reduce or eliminate ambient light contamination to optically sensitive components in a syringe.

The invention discloses a method for creating a attenuation image of a measured object based on computer tomography CT and an apparatus thereof. The method is characterized by: firstly, establishing a line attenuation coefficient transformation model according to the measured object and creating an initial model parameter to describe the line attenuation coefficient transformation model; using the line attenuation coefficient transformation model to carry out transformation to an image element of a CT image of the measured object so as to obtain an initial attenuation image of the measured object and an initial attenuation projection image; according to the initial attenuation projection image and a continuous consistency condition satisfied by the attenuation projection image and the projection image of radioactive drug distribution, correcting an initial model parameter; redescribing the line attenuation coefficient transformation model by using the corrected model parameter so as to obtain a final attenuation image of the measured object. By using the method, the line attenuation coefficient transformation model parameter can be accurately and conveniently obtained. Therefore, the measured object attenuation image based on the CT can be effectively created.

Systems, devices, and methods are provided that facilitate synthesis and analysis of chemical compounds on a convenient and automatable palette-based platform. Palettes utilized for analysis support a variety of functional sites, including test wells, separation devices, and test sites that have rapid thermal equilibration, on a single test fixture. This permits both the performance of a wide variety of tests and of tests with different temperature requirements or responses in parallel, on the same test fixture. Such systems, devices, and methods are particularly suitable for production and characterization of radiopharmaceuticals.